Sangamo Therapeutics Inc (NASDAQ:SGMO) CFO Kathy Yi sold 5,000 shares of the company’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $14.66, for a total value of $73,300.00. Following the completion of the sale, the chief financial officer now owns 12,250 shares in the company, valued at $179,585. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Kathy Yi also recently made the following trade(s):

  • On Thursday, August 16th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $15.39, for a total value of $76,950.00.
  • On Monday, July 16th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $14.77, for a total value of $73,850.00.

Shares of SGMO stock traded up $0.50 during trading hours on Tuesday, hitting $15.20. 1,638,400 shares of the company’s stock were exchanged, compared to its average volume of 2,345,505. The company has a debt-to-equity ratio of 0.07, a quick ratio of 7.24 and a current ratio of 7.24. The stock has a market capitalization of $1.51 billion, a PE ratio of -21.71 and a beta of 2.94. Sangamo Therapeutics Inc has a 52 week low of $11.30 and a 52 week high of $27.50.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The business had revenue of $21.42 million for the quarter, compared to the consensus estimate of $21.43 million. Sangamo Therapeutics had a negative return on equity of 26.36% and a negative net margin of 105.65%. Sangamo Therapeutics’s revenue for the quarter was up 159.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.17) EPS. analysts forecast that Sangamo Therapeutics Inc will post -0.69 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in SGMO. First Mercantile Trust Co. lifted its stake in shares of Sangamo Therapeutics by 93.7% during the first quarter. First Mercantile Trust Co. now owns 7,666 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 3,708 shares during the period. Leisure Capital Management lifted its stake in shares of Sangamo Therapeutics by 9.3% during the second quarter. Leisure Capital Management now owns 43,676 shares of the biopharmaceutical company’s stock valued at $620,000 after acquiring an additional 3,714 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Sangamo Therapeutics by 7.7% during the first quarter. Principal Financial Group Inc. now owns 54,480 shares of the biopharmaceutical company’s stock valued at $1,035,000 after acquiring an additional 3,910 shares during the period. Amalgamated Bank lifted its stake in shares of Sangamo Therapeutics by 38.4% during the second quarter. Amalgamated Bank now owns 15,478 shares of the biopharmaceutical company’s stock valued at $220,000 after acquiring an additional 4,294 shares during the period. Finally, Xact Kapitalforvaltning AB lifted its stake in shares of Sangamo Therapeutics by 42.5% during the second quarter. Xact Kapitalforvaltning AB now owns 17,446 shares of the biopharmaceutical company’s stock valued at $248,000 after acquiring an additional 5,200 shares during the period. Institutional investors own 63.84% of the company’s stock.

SGMO has been the topic of a number of analyst reports. BidaskClub upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 20th. Bank of America began coverage on Sangamo Therapeutics in a report on Wednesday, June 20th. They set a “buy” rating and a $24.00 target price on the stock. Zacks Investment Research cut Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 17th. Cowen restated a “buy” rating on shares of Sangamo Therapeutics in a report on Monday, July 23rd. Finally, Wedbush restated a “hold” rating and set a $9.00 target price on shares of Sangamo Therapeutics in a report on Tuesday, July 24th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $21.00.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Further Reading: How to Use a Moving Average for TradingĀ 

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.